Little is known about the relevance of chromogranins (Cgs) and secretogranins (Sgs) in Parkinson's disease (PD). In this study, we determined serum levels of CgA, CgB, and SgII in PD patients and assessed their association with disease severity. PD patients were recruited, identified, and classified as having early (n = 14), intermediate (n = 18), or late (n = 4) stage disease according to Hoehn-Yahr scores. The serum concentrations of CgA, CgB, and SgII in patients with well-defined PD (n = 36) and in healthy controls (n = 52) were measured by enzyme-linked immunosorbent assay.
| INTRODUCTION
Parkinson's disease (PD), first described in 1817, is a progressive neurodegenerative disease that is common in elderly people, with a worldwide prevalence of 1% and 4% in persons aged over 60 and 80 years old, respectively 1 . The main pathology hallmarks of PD are region-specific selective degeneration of dopaminergic, neuromelanin-containing neurons from the pars compact of the substantia nigra, the formation of Lewy bodies in the residual patina, and the proliferation of glial cells. 2 Clinical features include tremor at rest, rigidity, bradykinesia, postural instability, and non-motor symptoms. 3 The etiology and pathogenesis of PD have not been fully elucidated, but factors that might contribute to this disease include genetic susceptibility, 4, 5 oxidative stress, 6 mitochondrial dysfunction, neuroinflammation, an altered immune response, neuron apoptosis, and protein dysfunction. 7 Many studies have focused on discovering early diagnostic biomarkers from serum, plasma, and cerebrospinal fluid (CSF) in order to reduce the economic impact of PD in an aging society. Using the significant association between Aβ42 and 18 F-6-fluoro-L-dopa uptake for positron emission tomography scans, CSF levels of Aβ42 and tau have been shown to correlate with lower striatal dopaminergic function. 8 Another study found decreased levels of both DJ-1 and α-synuclein in CSF from patients with PD vs controls and patients with Alzheimer's disease when the analysis was controlled for blood contamination. However, with cut-off values of 40 ng/mL and 0.5 ng/mL for DJ-1 and α-synuclein, respectively, the sensitivity and specificity for identifying patients with PD were 90% and 70% for DJ-1 and 92% and 58% for α-synuclein. Moreover, combining the two biomarkers did not enhance the power of PD diagnosis, and the CSF levels of DJ-1 and α-synuclein
were not associated with PD severity. 9 Thus, there is still a need for new biomarkers that can be used in the diagnosis of PD.
Recent studies have suggested that chromogranins (Cgs) and secre- 15 (early: score = 1-2.5, n = 14; intermediate: score = 3, n = 18; late: score = 4-5, n = 4). PD patients were also given the mean unified PD rating scale (UPDRS) score. 16 Age-and gender-matched healthy control subjects were recruited from the Physical Check Center of at the same hospital. Demographics of patients and controls are described in Table 1 
| Chromogranin and secretogranin analysis
Venous blood (10 mL) was collected from participants, all of whom were free of acute infection and acute stress at the time of blood collection. Serum was collected in lithium heparin tubes and harvested by centrifugation at 3000g for 10 min, divided into aliquots, and frozen at −80 C until use. Serum levels of CgA, CgB, and SgII were measured using commercially available ELISA kits purchased from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions.
| Statistical analysis
SPSS Statistics version 18.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Continuous variables are presented as the mean ± SD, and a Student's t test was used to determine whether there was a significant difference between two groups. The normal distribution test was carried out first, and a non-parametric test was used to determine whether there was a significant difference of Serum CgA, CgB, and SgII Levels between two groups，then Kruskal Wallis test was employed to determine the significant difference of biomarker concentrations among the patients with difference PD stages. Finally, Spearman correlation analysis was used to determine whether CgA and SgII levels correlated with PD severity. All P values are presented as two-tailed, and differences were considered significant at P < 0.05.
3 | RESULTS
| Demographic and clinical characteristics of the study population
The demographics and clinical characteristics of patients with PD and healthy controls were compared (Table 1) 3.2 | Serum CgA, CgB, and SgII levels in patients and controls
Serum levels of CgA, CgB, and SgII were measured using conventional enzyme-linked immunosorbent assays (ELISA). The level of CgA was significantly higher in PD patients (33.10 ± 4.03 ng/mL) than in the control group (12.95 ± 1.34 ng/mL, P < 0.05, Figure 1A ), whereas the level of SgII was significantly lower in PD patients (30.93 ± 3.36 ng/mL) than in controls (43.86 ± 4.08 ng/mL, P < 0.05, Figure 1C ). There was no significant difference between the serum levels of CgB in PD patients (93.05 ± 26.63 ng/mL) and controls (176.6 ± 34.62 ng/mL, P = 0.08, Figure 1B ). Figure 2A ), and SgII levels were 42.31 ± 4.65, 28.20 ± 4.17, and 3.45 ± 0.27 ng/mL, respectively (P < 0.05 and < 0.01, Figure 2B ). 
| Correlation of serum CgA and SgII levels with Hoehn-Yahr and UPDRS scores

| DISCUSSION
The granin family consists of soluble single-chain glycoproteins, including Cgs and Sgs, which are widely distributed in the nervous system, endocrine system, and immune system. 18 Granins are the major proteins in the core of secretory granules, where they may account for up to 80% of the total core proteins. Cgs and Sgs are involved in gastrointestinal endocrine tumors, neuroendocrine tumors, metabolic disease, and cardiovascular disease. [19] [20] [21] Currently, it is not known whether the granin family plays a role in neurodegenerative diseases such as PD. Here, we investigated the correlation between serum levels of three granins (CgA, CgB, and SgII) and PD severity.
We found that the concentration of serum CgA was significantly higher in PD patients than in the control group and that the concentration increased progressively from the early to late disease stage. Moreover, we found that CgA levels correlated with Hoehn-Yahr and UPDRS scores.
There was no difference in serum CgB levels between PD patients and healthy controls. The CgA results are consistent with several lines of evidence that may suggest mechanisms for the involvement of CgA in PD. First, Lewy bodies, which are mainly made up of α-synuclein, are widely distributed in the cerebral cortex, mesencephalon, and brain stem. 3, 22 It has been shown that some areas of the brain in patients contain both α-synuclein and tau. 23 A high concentration of tau can stimulate aggregation of α-synuclein, eventually leading to formation of Lewy bodies. 24 Moreover, tau can enhance the damage to neuronal cells caused by α-synuclein. CgA can stimulate production of tau, 25 suggesting that CgA may also affect aggregation of α-synuclein via tau pathway.
Second, the stimulation and proliferation of glial cells are important pathological changes in PD patients, 5 and CgA may activate glial cells, 26 which could potentially accelerate the loss of dopaminergic neurons.
Third, oxidative stress in PD patients results in lipid peroxidation and mitochondrial dysfunction, thereby resulting in an energy deficit and loss of dopaminergic neurons. 27 CgA can counter the onset of oxidative stress by regulating Ca 2+ channels in the plasma membrane. 28 Fourth, CgA affects immune function by inhibiting the migration of inflammatory cells, and PD patients often present with immune dysfunction. 29 We also found that the concentration of serum SgII was significantly lower in PD patients than in the control group, that it decreased progressively from the early to late stage, and that it correlated with Hoehn-Yahr and UPDRS scores. PD is characterized by neuronal dysfunction and degeneration. A decrease in the concentration of SgII has been shown to reflect neuronal activity. 30 In the substantia nigra, accumulation of α-synuclein leads to a decline in dopamine level, which eventually reduces SgII level 31 because serum dopamine can activate the gene encoding SgII. 32 Ultimately, a decrease in SgII concentration limits its beneficial roles in inhibiting inflammation, stimulating axonal growth, and repairing vascular endothelial cells, 33, 34 perhaps resulting in the dysfunction of neuronal protection during the disease progress of PD.
In this study, it was found that the levels of CgA and SgII showed reverse patterns depend upon the severity of PD. In the severer PD patients, CgA level was increasing but SgII level was decreasing. This discovery was consistent with the results reported by Eder et al. 10 CgA was currently recognized a pro-inflammatory factor [35] [36] [37] which could enhance the neuroinflammatory effects in the pathogenesis of PD. 38 SgII was thought a neuroprotector which could inhibit the neuroinflammatory response. 17, 32, 39 In severer PD patients, the decreasing level of SgII might lose the neuroprotection functions. Taken together, our results suggest that CgA and SgII may be useful new biomarkers for the early diagnosis and staging of PD and for monitoring prognosis after medication. This study has some limitations. First, the sample size in the study was small, and therefore randomized control trials are needed to verify our results.
Second, this was a cross-sectional study of CgA and SgII levels, and further prospective studies are needed to elucidate the role of these granins in PD.
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